irritable bowel syndrome

[Nature Reviews Gastroenterology & Hepatology] The authors provide a summary of the role of bile acids (BAs) and their disrupted homeostasis in the development of gastrointestinal and hepatic disorders and present novel insights on how targeting BA pathways might contribute to novel treatment strategies for these disorders.

[Biomerica, Inc. (GlobeNewswire, Inc.)] Biomerica, Inc. announced that the Canadian Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the company’s InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from IBS.

[Scientific Reports] Scientists investigated if remodeling of the intestinal basement membrane type VI collagen was associated with pathophysiological changes in Crohn’s disease and ulcerative colitis.

[Knight Therapeutics Inc.] Knight Therapeutics, Inc. announced the Canadian commercial availability of IBSRELA, a first-in-class therapy for the treatment of IBS with constipation in adults.

[Nature] Scientists showed that a bacterial infection and bacterial toxins could trigger an immune response that led to the production of dietary-antigen-specific IgE antibodies in mice, which were limited to the intestine.

[Seed Health Inc. (PRNews] The regulatory acceptance enables a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities.